Neuronetics reported total revenue of $42.0 million for the third quarter of 2026, a 12.5% increase year-over-year that surpassed analyst projections. The company demonstrated significant progress toward profitability, narrowing its net loss to $0.02 per share compared to a loss of $0.13 in the prior-year period, supported by record performances in both its clinic network and system sales segments.
Key Highlights
- Greenbrook clinic revenue reached a record $26.2 million, growing 20.1% year-over-year as the company integrated care and improved revenue cycle management.
- Gross margin expanded significantly to 52.2% from 45.9% in Q3 2025, driven by the new go-to-market strategy and operational efficiencies within clinics.
- Operating expenses decreased 13% to $21.3 million, and the company adjusted its full-year 2026 OpEx guidance downward to $92.5 million–$95.5 million.
- The company submitted a 510(k) application for an accelerated TMS protocol and signed a distribution agreement with Wave Neuro to pursue PTSD treatment capabilities.